GlobalData Plc

BIO Webinar- Pharma Trends in Emerging Markets

Industry as it stands now

Slow growth in pharmaceutical sales over recent years has spurred considerable interest and investment into emerging global markets: Brazil, Russia, India, China and South Korea (BRICS). The main reason behind this trend is cost efficiency of establishing off-shore manufacturing sites in those countries; and also setting them as new target markets, given their ever evolving demographics, healthcare affordability and accessibility. Over the past 6 years, company revenue compound average growth rates (CAGR) in Russia, India, China and South Korea averaged at 7.2%, exceeding that of US where a CAGR of 6% was observed.

GlobalData Insights & Analysis related to this topic

Research was conducted so as to assess the potential and examine current trends in the pharmaceutical industry in Brazil, Russia, India, China and South Korea. Deal trends show China and India are ahead of all other regions with respect to the number of M&A and licensing agreement deals per year, and annual deal value. Nevertheless, Brazil was calculated to have the highest value per deal overall.

When comparing products marketed in the past 10 years, every emerging region displayed an interesting focus shift in its pipeline portfolio, both in terms of therapy areas and development in product type. Infectious Disease is no longer the primary therapy area of focus in these countries, nowadays the majority of development is in oncology. Furthermore, a sharp increase in biosimilar development has been observed with respect to the past 10 years.

Analyst’s Opinion

GlobalData Senior Analyst within Sales Analytics Chloe Thornton suggests this analysis has “highlighted some interesting and driving topics that will promote activity in Brazilian, Russian, Indian, Chinese and South Korean pharmaceutical markets. Given the progress being made in these regions in terms of healthcare accessibility, insurance coverage and drug regulation, they remain as a relatively untapped resource”. While it is established that these markets do show promising growth, this potential could be hampered by certain region specific challenges, which are also explored in the ‘Pharma Trends in Emerging Markets’ webinar.

Editor’s notes

– Comments provided by Chloe Thornton, Senior Analyst at GlobalData.

– Information based on GlobalData’s webinar: Pharma Trends in Emerging Markets

– This webinar was organised in partnership with BIO International Convention (San Diego, June 19-22 2017)

Related Intelligence

Want more Insight like this?

Our interactive subscription platform has the most comprehensive data and analysis in your industry.

Request a Demo

Related Consulting

How can we help your business?

Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual requirements.

Request a Callback

    Press Release Healthcare

    Late-stage CKD-induced comorbidity therapeutics market to reach $10.5bn by 2026

    Sales for chronic kidney disease (CKD)-induced hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK) therapeutics were estimated to be $4.2bn across the seven major markets (7MM*) in 2016. This is expected to grow to $10.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 9.5%, according to GlobalData, a leading data and analytics company.

    Press Release Healthcare

    Majority of oncology clinical trials in China failed to meet enrolment targets

    The majority of oncology clinical trials in China that had a start date between 1 January 2012 and 31 December 2017 failed to meet the planned enrolment targets, according to GlobalData, a leading data and analytics company. The company identified and analyzed enrollment efficiencies of 324 clinical trials during the period and found that on...

    Press Release Healthcare

    Need for supportive care in oncology will increase during the next decade

    The need for effective supportive care in oncology will increase in the next decade as patients continue to live longer and cancer progresses to become more like a chronic disease. This includes the need for chemotherapy-related conditions, as chemotherapy will remain the backbone of cancer therapy for the foreseeable future, observes GlobalData, a leading data and analytics company.

    Press Release Healthcare

    World Cancer Day: What will 2018 mean for cancer research and treatment?

    The theme of this year’s World Cancer Day held on 4th February of “We can. I can.” aimed to reinforce the public message that all individuals and groups can play their part in reducing the global burden of cancer. Indeed in recent years many events have involved collaborations between traditional drug developers, cancer treatment professionals and those of varying disciplines. Examples include the IBM Watson supercomputer which is helping physicians make treatment decisions and the development of other databases such as ASCO’s CancerLinQ which assists oncologists in monitoring and analyzing patient data.

    Press Release Healthcare

    Melanoma sales are projected to rise to $5.5bn in 2026

    The value of the melanoma market was estimated to be $3.3bn across the seven major markets (7MM*) in 2016. This is expected to grow to $5.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 5.3%, according to GlobalData, a leading data and analytics company.

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.

Emailpr@globaldata.com
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends… https://t.co/wJOJOqYIJF